Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Paul Bunn to Drug Administration Schedule

This is a "connection" page, showing publications Paul Bunn has written about Drug Administration Schedule.

 
Connection Strength
  
 
 
0.376
  
  1. Bunn PA. Diseases desperate grown. J Natl Cancer Inst. 2008 Apr 16; 100(8):520-1.
    View in: PubMed
    Score: 0.065
  2. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P, Bunn PA. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res. 2002 Mar; 8(3):904-12.
    View in: PubMed
    Score: 0.043
  3. Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3419-24.
    View in: PubMed
    Score: 0.036
  4. Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):559-67.
    View in: PubMed
    Score: 0.032
  5. Bunn PA, Kelly K. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-144-S12-148.
    View in: PubMed
    Score: 0.031
  6. Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23.
    View in: PubMed
    Score: 0.031
  7. Bunn PA, Kelly K. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1996 Dec; 23(6 Suppl 16):11-5.
    View in: PubMed
    Score: 0.030
  8. Bunn PA, Kelly KL. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60.
    View in: PubMed
    Score: 0.027
  9. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995 Jul; 13(7):1632-41.
    View in: PubMed
    Score: 0.027
  10. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge R, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10; 29(26):3567-73.
    View in: PubMed
    Score: 0.020
  11. Pisters KM, Kris MG, Bunn PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-41-S12-44.
    View in: PubMed
    Score: 0.008
  12. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30.
    View in: PubMed
    Score: 0.007
  13. Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J Clin Oncol. 1994 Sep; 12(9):1814-20.
    View in: PubMed
    Score: 0.006
  14. Brower M, Ihde DC, Johnston-Early A, Bunn PA, Cohen MH, Carney DN, Makuch RW, Matthews MJ, Radice PA, Minna JD. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med. 1983 Dec; 75(6):993-1000.
    View in: PubMed
    Score: 0.003
  15. Brower M, Carney DN, Ihde DC, Eddy J, Bunn PA, Cohen MH, Pelsor FR, Matthews MJ, Minna JD. High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung. Cancer. 1983 Nov 15; 52(10):1778-82.
    View in: PubMed
    Score: 0.003
  16. Morstyn G, Ihde DC, Eddy JL, Bunn PA, Cohen MH, Minna JD. Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. Am J Clin Oncol. 1983 Oct; 6(5):547-51.
    View in: PubMed
    Score: 0.003
  17. Krasnow S, Bunn PA, Ihde DC, Matthews MJ, Cohen MH, Eddy J, Minna JD. ICRF-159 in advanced gastric cancer. Absence of activity. Am J Clin Oncol. 1982 Dec; 5(6):635-9.
    View in: PubMed
    Score: 0.003
  18. Cohen MH, Ihde DC, Bunn PA, Fossieck BE, Matthews MJ, Shackney SE, Johnston-Early A, Makuch R, Minna JD. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep. 1979 Feb; 63(2):163-70.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)